These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 16842462

  • 1. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):351-9. PubMed ID: 16842462
    [Abstract] [Full Text] [Related]

  • 2. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 15; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 3. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL, García-Paredes J, Cruz Santamaria DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, Díaz-Rubio M.
    Rev Esp Enferm Dig; 2002 May 15; 94(5):269-79. PubMed ID: 12474335
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec 15; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 7. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M, Italian Multicentric Study Group on Infliximab.
    Dig Liver Dis; 2005 Aug 01; 37(8):577-83. PubMed ID: 15886081
    [Abstract] [Full Text] [Related]

  • 8. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov 01; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 9. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep 01; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

  • 10. Infliximab in Crohn's disease: first anniversary clinical experience.
    Cohen RD, Tsang JF, Hanauer SB.
    Am J Gastroenterol; 2000 Dec 01; 95(12):3469-77. PubMed ID: 11151879
    [Abstract] [Full Text] [Related]

  • 11. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec 01; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 12. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical outcome of Crohn's disease treated with infliximab.
    Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tözün N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dökmeci A.
    Hepatogastroenterology; 2003 Feb 13; 50(52):952-6. PubMed ID: 12845957
    [Abstract] [Full Text] [Related]

  • 15. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ.
    Am J Gastroenterol; 2001 Mar 13; 96(3):722-9. PubMed ID: 11280541
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J.
    Scand J Gastroenterol; 2002 Jul 13; 37(7):818-24. PubMed ID: 12190096
    [Abstract] [Full Text] [Related]

  • 18. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 13; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 19. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
    Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA.
    Am J Gastroenterol; 2000 Dec 13; 95(12):3490-7. PubMed ID: 11151882
    [Abstract] [Full Text] [Related]

  • 20. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.
    Aliment Pharmacol Ther; 2008 Jul 13; 28(2):221-7. PubMed ID: 18485127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.